维普中文期刊产品整合服务
88篇 您的检索式:作者名="MESA S"
    题名 作者 年代 出处 被引量
1在经历 transcatheter 的病人的 atrial 纤维性颤动的临床、预示的含意大动脉的阀门培植显示文摘 AIM: To study a cohort of consecutive patients under-going transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR). METHODS: All consecutive patients undergoing TAVI in our hospital were included. The AF group comprised patients in AF at the time of TAVI or with history of AF, and were compared with the SR group. Procedural, echocardiographic and follow-up variables were compared. Likewise, the CHA 2 DS 2-VASC stroke risk score and HAS-BLED bleeding risk score and antithrombotic treatment at discharge in AF patients were compared with that in SR patients. RESULTS: From a total of 34 patients undergoing TAVI, 17 (50%) were allocated to the AF group, of whom 15 (88%) were under chronic oral anticoagulation. Patients in the AF group were similar to those in the SR group except for a trend (P = 0.07) for a higher logistic EuroSCORE (28% vs 19%), and a higher prevalence of hypertension (82% vs 53%) and chronic renal failure (17% vs 0%). Risk of both stroke and bleeding was high in the AF group (mean CHA 2 DS 2-VASC 4.3, mean HAS-BLED 2.9). In the AF group, treatment at discharge included chronic oral anticoagulation in all except one case, and in association with an antiplatelet drug in 57% of patients. During a mean follow-up of 11 mo (maximum 32), there were only two strokes, none of them during the peri-procedural period: one in the AF group at 30 mo and one in the SR group at 3 mo. There were no statistical differences in procedural success, and clinical outcome (survival at 1 year 81% vs 74% in AF and SR groups, respectively, P = NS). CONCLUSION: Patients in AF undergoing TAVI show a trend to a higher surgical risk. However, in our cohort, patients in AF did not have a higher stroke rate compared to the SR group, and the prognosis was similar in both groups.Pablo Salinas Raúl Moreno Luis Calvo Santiago Jiménez-Valero Guillermo Galeote Angel Sánchez-Recalde Teresa López-Fernández Sergio Garcia-Blas Diego Iglesias Luis Riera Isidro Moreno-Gómez Jose María Mesa Ignacio Plaza Rocio Ayala Rosa Gonzalez José-Luis López-Sendón 2012World Journal of Cardiology2012,4,1:2
2Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis显示文摘VERSTOVSEK S KANTARJIAN H MESA RA 2010NEnglJMed2010,363,12:1
3Use of the functional assessment of cancer therapy-anemia in persons with myelo- proliferative neoplasm-associated myelofibrosis and anemia 显示文摘Tefferi A Hudgerns S Mesa R 2014Clin Ther2014,36,4:1
4A NewLayered lnorganic-orgnic Hybrid Manganese(II)Phosphite:(C2H10N2)[Mn3(HPO3)4]:Hydrothermal Synthesis ,Crystal Struture ,and spectroscopic and Magnetic Propertics显示文摘Fernandez S Mesa J L Pizarro J L 0,,12:1
5UV-B-induced DNA damage and repair in the mouse lens显示文摘Mesa R Bassnett S 2013Invest Ophthalmol Vis Sci2013,54,10:1
6The major genetic determinants of HIV-1control affect HLA class I peptide presentation显示文摘International HIV Controllers Study Pereyra F Jia X McLaren P J Telenti A de Bakker P I Walker B D Ripke S Brumme C J Pulit S L Carrington M Kadie C M Carlson J M Heckerman D Graham R R Plenge R M Deeks S G Gianniny L Crawford G Sullivan J Gonzalez E Davies L Camargo A Moore JM Beattie N Gupta S Crenshaw A Burtt N P Guiducci C Gupta N Gao X Qi Y Yuki Y Piechocka-Trocha A Cutrell E Rosenberg R Moss K L Lemay P O'Leary J Schaefer T Verma P Toth I Block B Baker B Rothchild A Lian J Proudfoot J Alvino D M Vine S Addo M M Allen T M Altfeld M Henn M R Le Gall S Streeck H Haas D W Kuritzkes D R Robbins G K Shafer R W Gulick R M Shikuma C M Haubrich R Riddler S Sax P E Daar E S Ribaudo H J Agan B Agarwal S Ahern R L Allen B L Altidor S Altschuler E L Ambardar S Anastos K Anderson B Anderson V Andrady U Antoniskis D Bangsberg D Barbaro D Barrie W Bartczak J Barton S Basden P Basgoz N Bazner S Bellos N C Benson A M Berger J Bernard N F Bernard A M Birch C Bodner S J Bolan R K Boudreaux E T Bradley M Braun J F Brndjar J E Brown S J Brown K Brown S T Burack J Bush LM Cafaro V Campbell O Campbell J Carlson R H Carmichael J K Casey K K Cavacuiti C Celestin G Chambers S T Chez N Chirch L M Cimoch P J Cohen D Cohn LE Conway B Cooper D A Cornelson B Cox D T Cristofano M V Cuchural G Jr Czartoski J L Dahman J M Daly J S Davis B T Davis K Davod S M DeJesus E Dietz C A Dunham E Dunn M E Ellerin T B Eron J J Fangman J J Farel C E Ferlazzo H Fidler S Fleenor-Ford A Frankel R Freedberg K A French N K Fuchs JD Fuller J D Gaberman J Gallant J E Gandhi R T Garcia E Garmon D Gathe J C Jr Gaultier C R Gebre W Gilman F D Gilson I Goepfert P A Gottlieb M S Goulston C Groger R K Gurley T D Haber S Hardwicke R Hardy W D Harrigan P R Hawkins T N Heath S Hecht F M Henry W K Hladek M Hoffman R P Horton J M Hsu R K Huhn G D Hunt P Hupert M J Illeman M L Jaeger H Jellinger R M John M Johnson J A Johnson K L Johnson H Johnson K Joly J Jordan W C Kauffman C A Khanlou H Killian R K Kim A Y Kim D D Kinder C A Kirchner J T Kogelman L Kojic E M Korthuis P T Kurisu W Kwon D S LaMar M Lampiris H Lanzafame M Lederman M M Lee D M Lee J M Lee M J Lee E T Lemoine J Levy J A Llibre J M Liguori M A Little S J Liu A Y Lopez A J Loutfy M R Loy D Mohammed D Y Man A Mansour M K Marconi V C Markowitz M Marques R Martin J N Martin H L Jr Mayer K H McElrath M J McGhee T A McGovern B H McGowan K McIntyre D Mcleod GX Menezes P Mesa G Metroka CE Meyer-Olson D Miller A O Montgomery K Mounzer K C Nagami E H Nagin I Nahass R G Nelson M O Nielsen C Norene D L O'Connor D H Ojikutu B O Okulicz J Oladehin O O Oldfield E C Olender S A Ostrowski M Owen WF Jr Pae E Parsonnet J Pavlatos A M Perlmutter A M Pierce M N Pincus J M Pisani L Price L J Proia L Prokesch R C Pujet H C Ramgopal M Rathod A Rausch M Ravishankar J Rhame F S Richards C S Richman D D Rodes B Rodriguez M Rose R C 3rd Rosenberg E S Rosenthal D Ross P E Rubin D S Rumbaugh E Saenz L Salvaggio M R Sanchez WC Sanjana V M Santiago S Schmidt W Schuitemaker H Sestak P M Shalit P Shay W Shirvani V N Silebi V I Sizemore J M Jr Skolnik P R Sokol-Anderson M Sosman J M Stabile P Stapleton J T Starrett S Stein F Stellbrink H J Sterman FL Stone V E Stone D R Tambussi G Taplitz R A Tedaldi E M Telenti A Theisen W Torres R Tosiello L Tremblay C Tribble M A Trinh P D Tsao A Ueda P Vaccaro A Valadas E Vanig T J Vecino I Vega V M Veikley W Wade B H Walworth C Wanidworanun C Ward D J Warner D A Weber R D Webster D Weis S Wheeler D A White D J Wilkins E Winston A Wlodaver C G van't Wout A Wright D P Yang O O Yurdin D L Zabukovic B W Zachary K C Zeeman B Zhao M 2010Science2010,330,6010:1
7A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis 显示文摘VERSTOVSEK S MESA RA GOTLIB J 2012NEnglJMed2012,366,9:1
8Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibosis 显示文摘Verstovsek S Kantar JH Mesa RA 2010N Engl J Med2010,363,12:1
9Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis显示文摘Verstovsek S Kantarjian H Mesa RA 2010N Engl J Med2010,363,:1
10A double -blind, placebo - controlled trim of ruxolitinib for myelofibrosis 显示文摘Verstovsek S Mesa RA Goflib J 2012New Engl J Med2012,366,:1
11Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans 显示文摘Kew S Mesa M D Tricon S 2004Am J Clin Nutr2004,79,4:1
12A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis 显示文摘Verstovsek S Mesa RA Gotlib J 2012N Engl J Med2012,366,9:1
13A double-blind, placebo- controlled trial of ruxolitinib for myelofibrosis 显示文摘Verstovsek S Mesa RA Gotlib J 2012N Engl J Med2012,366,9:1
14A double-blind, placebo- controlled trial of ruxolitinib for myelofibrosis 显示文摘Verstovsek S Mesa RA Godib J 2012N Engl J Med2012,366,9:1
15A double-blind, placebo controlled trial of ruxolitinib for myelofibrosis 显示文摘Verstovsek S Mesa RA Gotlib J 2012N Engl J Med2012,366,9:1
16Safety and efficacy of INCB018424,a JAK1 and JAK2 inhibitor,in myelofibrosis显示文摘Verstovsek S Kantarjian H Mesa RA 2010NEnglJ Med2010,363,12:1
17Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans显示文摘Kew S Mesa MD Tricon S 2004Am J Clin Nutr2004,79,4:1
18A double - blind, place- bo- controlled trial of ruxolitinib for myelofibrosis显示文摘Verstovsek S Mesa RA Gotlib J 2012N Engl J Med2012,366,9:1
19Effects of oilsrich ineicosapentaenoic and docosahexaenoic acids on im-mune cellcomposition and function in healthy humans显示文摘Kew S Mesa MD Tricon S 2004Am J Clin Nutr2004,79,:1
20The Myelofibrosis Symptom As- sessment Form(MFSAF) :an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibresis 显示文摘Mesa RA Schwager S Radia D 2009Leuk Res2009,33,9:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费